Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration.
CONCLUSION: PVD was not found to impact functional and anatomical outcomes of T&E ranibizumab therapy. However, patients without a complete PVD required more retreatments and were significantly less likely to be successfully extended. TRIAL REGISTRATION NUMBER: NCT01948830. PMID: 31563866 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - September 28, 2019 Category: Opthalmology Authors: Waldstein SM, Coulibaly L, Riedl S, Sadeghipour A, Gerendas BS, Schmidt-Erfurth UM Tags: Br J Ophthalmol Source Type: research

Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA.
This study aimed to elucidate visual benefits of ranibizumab in patients with neovascular age-related macular degeneration (nAMD) compared with control arms and identify factors affecting response. METHODS: This is a post-hoc pooled analysis of two phase III studies, ANCHOR and MARINA, of ranibizumab for the treatment of nAMD. ANCHOR included 83 international sites. MARINA included 96 sites in the USA. Analysis included patients (control, n=323; ranibizumab, n=332) with nAMD and a baseline best-corrected visual acuity (BCVA) of ≥35-69 letters. Patients with the highest baseline BCVA had lowest BCVA gains. Ranibizum...
Source: The British Journal of Ophthalmology - September 27, 2019 Category: Opthalmology Authors: Tufail A, Margaron P, Guerin T, Larsen M Tags: Br J Ophthalmol Source Type: research

Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab
Conclusion: The odds of endophthalmitis with aflibercept and ranibizumab combined were higher compared with the sterilely preloaded bevacizumab, arguing for a safety advantage of sterile preloading of anti–vascular endothelial growth factor injections. (Source: RETINA)
Source: RETINA - September 24, 2019 Category: Opthalmology Tags: Original Study Source Type: research

RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study
Purpose: To evaluate the efficacy and safety of 2 dosing regimens of ranibizumab 0.5 mg versus verteporfin photodynamic therapy in Asian patients with visual impairment due to myopic choroidal neovascularization. Methods: Eligible patients (aged ≥18 years) were randomized 2:2:1 to Group I (n = 182; ranibizumab treatment guided by visual acuity stabilization criteria); Group II (n = 184; ranibizumab treatment guided by disease activity); or Group III (n = 91; verteporfin photodynamic therapy on Day 1; from Month 3, ranibizumab/verteporfin photodynamic therapy/both treatment guided by disease activity). Results: T...
Source: RETINA - September 24, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Treatment outcomes of pachychoroid neovasculopathy with photodynamic therapy and anti-vascular endothelial growth factor
Conclusion: PDT with or without ranibizumab appears to be an effective treatment modality for PNV. (Source: Indian Journal of Ophthalmology)
Source: Indian Journal of Ophthalmology - September 23, 2019 Category: Opthalmology Authors: Rupak Roy Kumar Saurabh Dhaivat Shah Sugandha Goel Source Type: research

Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids
AbstractPurposeTo assess and compare early changes in neuroinflammatory and vascular parameters in diabetic macular edema (DME) with subfoveal neuroretinal detachment (SND) after treatment with intravitreal dexamethasone (DEX-I) and ranibizumab (IVR).MethodsThirty-three eyes (33 patients) with treatment na ïve DME with SND were retrospectively evaluated at baseline and 2 months after DEX-I (15 eyes) and 1 month after 3 monthly IVR injections (18 eyes). Inclusion criteria were: complete eye examination, good quality OCT and OCT-A images. OCT parameters included: central macular thickness (CMT); numb er of hyp...
Source: Acta Diabetologica - September 21, 2019 Category: Endocrinology Source Type: research

Notch Signaling Pathway Is Involved in bFGF-Induced Corneal Lymphangiogenesis and Hemangiogenesis.
Conclusion: The notch signaling pathway plays a role in regulating VEGF expression, affecting corneal lymphangiogenesis and hemangiogenesis in mice. The molecular imaging probe technique can visualize the changes in the VEGF-A expression level of corneal limbus hemangiogenesis. PMID: 31531237 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - September 20, 2019 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy
AbstractPurpose of ReviewDiabetic macular edema (DME) and complications of proliferative diabetic retinopathy (PDR) are the primary causes of vision loss in patients with diabetic retinopathy. As the incidence of diabetes increases worldwide, new, cost-effective treatments for DME and PDR will become paramount. Currently, anti-vascular endothelial growth factor (anti-VEGF) medications are considered first-line treatment. However, multiple visits for injections and the economic and time burden they entail make this treatment modality less than ideal. Early vitrectomy as well as depot delivery systems for medications could p...
Source: Current Diabetes Reports - September 16, 2019 Category: Endocrinology Source Type: research

Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.
Authors: Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA Abstract Introduction: The Tie-2/Angiopoietin pathway is therapeutic target in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Activation of Tie-2 receptor via Ang-1 maintains vascular stability to limit exudation. Ang-2, a competitive antagonist to Ang-1, and VE-PTP, an endothelial-specific phosphatase, interfere with the Tie-2-Ang-1 axis, resulting in vascular leakage. Areas Covered: Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME. Nesvacumab is an Ang-2 inhi...
Source: Expert Opinion on Investigational Drugs - September 14, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
Publication date: Available online 12 September 2019Source: The LancetAuthor(s): Andreas Stahl, Domenico Lepore, Alistair Fielder, Brian Fleck, James D Reynolds, Michael F Chiang, Jun Li, Melissa Liew, Rainer Maier, Qi Zhu, Neil MarlowSummaryBackgroundDespite increasing worldwide use of anti-vascular endothelial growth factor agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular efficacy, the appropriate drug and dose, the need for retreatment, and the possibility of long-term systemic effects. We evaluated the efficacy and safety of intravitreal ranibizumab compared with laser therap...
Source: The Lancet - September 14, 2019 Category: General Medicine Source Type: research

Recurrence of SRF Post Intravitreal Ranibizumab for Pediatric Choroidal Neovascularisation Secondary to Best Disease.
We present five cases of choroidal neovascularization secondary to pediatric Best disease which were treated with two different doses of intravitreal ranibizumab. Optical coherence tomography was used for monitoring of the cases. Three cases had subretinal fibrosis at presentation and two out of these 3 cases required repeat intravitreal ranibizumab at one year follow-up due to recurrence of subfoveal subretinal fluid. PMID: 31509457 [PubMed - as supplied by publisher] (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - September 13, 2019 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a U.S. perspective: analysis of 2-year Protocol T data.
Conclusions: This analysis suggests that aflibercept is not cost-effective versus ranibizumab for patients with DME, regardless of baseline vision. PMID: 31502893 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - September 12, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Ranibizumab Alters Levels of Intraocular Soluble Cytokine Receptors in Patients with Diabetic Macular Edema.
Abstract Purpose: Ranibizumab, an anti-VEGF-A (vascular endothelial cell growth factor-A) monoclonal antibody fragment, is a well-established treatment for diabetic patients with macular edema. However, very little is known about the effect of ranibizumab on intraocular regulation of pro- and anti-inflammatory signaling pathways and their regulation of VEGF family members, which was the aim of this study. Materials and Methods: Diabetic patients (n=10) aged ≥18 years with central diabetic macular edema, BCVA>24 and
Source: Current Eye Research - September 5, 2019 Category: Opthalmology Authors: Coughlin BA, Guha-Niyogi P, Sikorskii A, Glazer LC, Mohr S Tags: Curr Eye Res Source Type: research

Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
Abstract PURPOSE: To compare the 2-year outcomes of combination therapy using intravitreal ranibizumab and photodynamic therapy with those of fixed-dosing intravitreal aflibercept monotherapy as initial treatment for treatment-naïve polypoidal choroidal vasculopathy. METHODS: We retrospectively reviewed 63 eyes of 61 patients with treatment-naïve polypoidal choroidal vasculopathy who had undergone at least 24 months of follow-up. In total, 43 eyes underwent intravitreal ranibizumab-photodynamic therapy combination therapy and 20 eyes underwent fixed-dosing intravitreal aflibercept monotherapy. Visua...
Source: European Journal of Ophthalmology - September 2, 2019 Category: Opthalmology Authors: Yoneda A, Wakiyama H, Kurihara J, Kitaoka T Tags: Eur J Ophthalmol Source Type: research

Bilateral proliferative retinopathy and ischemic optic neuropathy in a patient with atypical hemolytic-uremic syndrome: A case report
Rationale: To report a rare case of severe atypical hemolytic-uremic syndrome (HUS) in a patient who presented with vitreous hemorrhage and tractional retinal detachment (TRD) in both eyes. To our knowledge, this is the first reported case of atypical HUS complicated with bilateral TRD in the literature. Patient concerns: A 20-year-old man with atypical HUS demonstrated bilateral visual acuity of hand motion at 30 cm. Diagnoses: Dilated fundus examination revealed diffuse intraretinal hemorrhage with vascular engorgement, neovascularization of the disc, and neovascularization elsewhere bilaterally. Fluorescein an...
Source: Medicine - September 1, 2019 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Seeking Surrogate Markers for Diabetic Macular Edema
The use of spectral-domain optical coherence tomography (OCT) has revolutionized the management of diabetic macular edema (DME), because it has emerged as a quick and noninvasive method of determining response to treatment and need for additional treatment based on resolution of fluid and changes in retinal thickness. The presumption is that OCT morphological findings are a meaningful indicator of visual function. In this issue of JAMA Ophthalmology, the DRCR Retina Network assessed the association between changes in OCT central subfield thickness (CST) and visual acuity (VA) by analyzing pooled data from protocol T, which...
Source: JAMA Ophthalmology - September 1, 2019 Category: Opthalmology Source Type: research

Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab
To investigate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in patients with diabetic macular edema (DME) treated monthly with ranibizumab. (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - August 27, 2019 Category: Opthalmology Authors: Yuxiang Hu, Yi Cheng, Xiaoxuan Xu, Bo Yang, Feng Mei, Qiong Zhou, Li Yan, Jun Wang and Xiaorong Wu Tags: Research article Source Type: research

Assessment of patient pain experience during intravitreal ranibizumab and aflibercept injection
CONCLUSION: VAS pain scores in aflibercept group were found to be significantly higher than the scores in the ranibizumab group. (Source: Middle East African Journal of Ophthalmology)
Source: Middle East African Journal of Ophthalmology - August 26, 2019 Category: Opthalmology Authors: Burak Bilgin & #350;emsettin Bilak Source Type: research

PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?
Purpose: Among eyes with proliferative diabetic retinopathy, identify whether baseline characteristics impact the benefit of ranibizumab over panretinal photocoagulation (PRP) in DRCR.net Protocol S. Methods: Participants had proliferative diabetic retinopathy, visual acuity of 20/320 or better, and no previous PRP. Eyes were randomized to PRP or intravitreous 0.5-mg ranibizumab. Results: Ranibizumab was superior to PRP for change in visual acuity and development of vision-impairing central-involved diabetic macular edema over 2 years (P (Source: RETINA)
Source: RETINA - August 24, 2019 Category: Opthalmology Tags: Original Study Source Type: research

[Budget impact of the incorporation of second-line drug treatment for diabetic macular edema in the Brazilian Unified National Health System from the perspective of the Minas Gerais State Health Department, Brazil].
Abstract The study's objective was to perform budget impact assessment for the incorporation of second-line intravitreal antiangiogenic therapy for diabatic macular edema in the scope of the Brazilian Unified National Health System (SUS) in Minas Gerais state, Brazil, discussing the incorporation's state budget feasibility. The budget impact assessment was performed as a deterministic method according to Ministry of Health guidelines. The study included patients with probable first-line treatment failure in a five-year timeline for all the technologies assessed. The analysis included the drugs bevacizumab (off-lab...
Source: Cadernos de Saude Publica - August 22, 2019 Category: International Medicine & Public Health Authors: Izidoro JB, Piazza T, Andrade EIG, Alvares-Teodoro J Tags: Cad Saude Publica Source Type: research

Choroidal neovascularization in an adolescent with RDH12-associated retinal degeneration.
Conclusions: Choroidal neovascularization may be a unique occurrence in RDH12-associated retinal dystrophy. Successful treatment of the neovascularization could be accomplished with intravitreal antivasogenic therapy. PMID: 31424981 [PubMed - as supplied by publisher] (Source: Ophthalmic Genetics)
Source: Ophthalmic Genetics - August 21, 2019 Category: Opthalmology Tags: Ophthalmic Genet Source Type: research

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
, Igwe F, Ayan F Abstract BACKGROUND/AIMS: Prospective data on switching anti-vascular endothelial growth factors in patients with neovascular age-related macular degeneration (nAMD) who have previously shown no/partial response are limited. This prospective study assessed the effect of switching from aflibercept to ranibizumab on anatomical and functional outcomes in patients with persistent/recurrent disease activity. METHODS: SAFARI (NCT02161575) was a 6-month, prospective, single-arm study conducted in the UK and Germany. Patients, meeting strict eligibility criteria for one of two subgroups (primary trea...
Source: The British Journal of Ophthalmology - August 5, 2019 Category: Opthalmology Authors: Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri R Tags: Br J Ophthalmol Source Type: research

Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study
ConclusionBoth the groups had the similar visual outcome. However, the superior anatomical result was observed in dexamethasone implant group during this short follow-up. (Source: International Ophthalmology)
Source: International Ophthalmology - August 3, 2019 Category: Opthalmology Source Type: research

Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema
AbstractAimsTo analyze the visual outcome after early switch to dexamethasone (DEX) in eyes with diabetic macular edema previously treated with ranibizumab (RNB), based on structural spectral-domain optical coherence tomography (SD-OCT) features.MethodsRetrospective study of data from 28 eyes which  underwent a loading dose of three monthly RNB injections and were then shifted to DEX implant injection. SD-OCT analysis was performed before switch to DEX (week 12, 12W) according to the presence of integrity of ellipsoid zone (EZ) and external limiting membrane (ELM), disorganization of retinal inner layers (DRIL), and q...
Source: Acta Diabetologica - August 2, 2019 Category: Endocrinology Source Type: research

Role of Cytokines in Ranibizumab Therapy for Macular Edema in Patients with Central Retinal Vein Occlusion
Journal of Ocular Pharmacology and Therapeutics, Ahead of Print. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - August 2, 2019 Category: Opthalmology Authors: Ryosuke Matsushima Hidetaka Noma Kanako Yasuda Hiroshi Goto Masahiko Shimura Source Type: research

Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007–2016
Data regarding the safety of anti-vascular endothelial growth factor (anti-VEGF) treatment is limited. To compare the adverse events (AEs) induced by aflibercept and ranibizumab using a spontaneous reporting system and determine the signals. We used data from the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database (KIDS-KD), collected between 2007 and 2016. Differences in patient demographics, report type, reporter, causality, and serious-AEs between aflibercept and ranibizumab were compared. Metrics including proportional reporting ratio (PRR), reporting odds ratio (ROR), a...
Source: Medicine - August 1, 2019 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Choroidal Neovascularization in Age-Related Macular Degeneration After Intravitreal Aflibercept or Ranibizumab
This second analysis of data from 2 randomized clinical trials investigated the association of intravitreal aflibercept vs ranibizumab and baseline characteristics with fellow eye conversion in patients treated for neovascular age-related macular degeneration in 1 eye. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - August 1, 2019 Category: Opthalmology Source Type: research

Early recurrence of retinopathy of prematurity after initial intravitreal ranibizumab monotherapy —experience from a tertiary referral center in Abu Dhabi, UAE
To evaluate recurrence rate of retinopathy of prematurity (ROP) after initial intravitreal ranibizumab injection (IVR) monotherapy for infants with type 1 retinopathy of prematurity (zone I and posterior zone II) and threshold disease (Source: Journal of AAPOS)
Source: Journal of AAPOS - August 1, 2019 Category: Opthalmology Authors: Tin T. Chan, Abeer A. Al Ali, Ahmed A. ElBarky, Fiona F. Dean, Fatima F. Habroosh, Manal M. Alzaabi, Rawdha R. Al Nuaimi Source Type: research

Oxymetazoline: reduction of subconjunctival hemorrhage incidence after intravitreal injections.
CONCLUSION: Administration of topical oxymetazoline 30 minutes before IVI is a single, harmless, cost-effective intervention that decreases the incidence of subconjunctival hemorrhage. This may considerably improve patient treatment satisfaction and promote compliance to IVI therapy. PMID: 31358153 [PubMed - in process] (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - July 31, 2019 Category: Opthalmology Authors: Gonzalez-Saldivar G, Pita-Ortiz IY, Flores-Villalobos EO, Jaurrieta-Hinojos JN, Espinosa-Soto I, Rios-Nequis G, Ramirez-Estudillo A, Jimenez-Rodriguez M Tags: Can J Ophthalmol Source Type: research

INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT AT 2-MONTH INTERVALS REDUCES FOVEAL AVASCULAR ZONE ENLARGEMENT AND VISION LOSS IN RADIATION MACULOPATHY: A Pilot Study
Purpose: To evaluate, in eyes with radiation maculopathy, the effect of 2-month-interval anti–vascular endothelial growth factor therapy on best-corrected visual acuity and foveal avascular zone (FAZ) enlargement using optical coherence tomography angiography. Methods: Consecutive treatment-naive patients with radiation maculopathy after proton beam irradiation for choroidal melanoma were retrospectively included. Clinical and optical coherence tomography angiography data at baseline and the 6-month visit were recorded. Two independent observers measured FAZ area manually on 3 × 3-mm optical coherence tomo...
Source: RETINA - July 24, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Swept-source optical coherence tomography angiography of choroidal neovascularization in vertically oriented oval dome-shaped maculopathy
Aniruddha Agarwal, Kanika Aggarwal, Vishali Gupta, for the OCTA Study Group Indian Journal of Ophthalmology 2019 67(8):1368-1371 A 48-year-old female presented with complaints of recent onset diminution of vision of the left eye (OS) for the past 2 months. She was highly myopic and was using glasses for the past 30 years. Ocular examination revealed presence of a myopic fundus with high axial lengths in both the eyes. Fundus examination of the OS revealed a myopic tessellated fundus with prominent choroidal vessels and a blunted foveal reflex. There was a small pale whitish lesion just superior to the foveal center. Optic...
Source: Indian Journal of Ophthalmology - July 22, 2019 Category: Opthalmology Authors: Aniruddha Agarwal Kanika Aggarwal Vishali Gupta for the OCTA Study Group Source Type: research

Circulating endothelial and progenitor cells in age-related macular degeneration.
CONCLUSION: We reported higher levels of circulating endothelial cells in age-related macular degeneration patients in comparison with the control group, thereby supporting the hypothesis of an involvement of endothelial dysregulation in the age-related macular degeneration and a reduction of the endothelial progenitor cell level in neovascular age-related macular degeneration patients after three intravitreal injections of ranibizumab. PMID: 31328962 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 22, 2019 Category: Opthalmology Authors: Mucciolo DP, Marcucci R, Sodi A, Cesari F, Murro V, Rogolino A, Rizzo S, Giusti B, Virgili G, Prisco D, Gori AM Tags: Eur J Ophthalmol Source Type: research

Intravitreal Ziv-Aflibercept: A Comprehensive Review.
Conclusion: Further prospective, randomized studies of ziv-aflibercept are needed, particularly in eyes with nAMD. PMID: 31314638 [PubMed - as supplied by publisher] (Source: Seminars in Ophthalmology)
Source: Seminars in Ophthalmology - July 19, 2019 Category: Opthalmology Tags: Semin Ophthalmol Source Type: research

Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
There is no consensus on the optimal initial treatment for polypoidal choroidal vasculopathy (PCV). Our study aimed to report the efficacy of repeated injections of intravitreal ranibizumab with or without pho... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - July 19, 2019 Category: Opthalmology Authors: Xiaoya Gu, Xiaobing Yu and Hong Dai Tags: Research article Source Type: research

Quantification of anterior chamber reaction after intravitreal injections of conbercept and ranibizumab: a pilot study
Eye, Published online: 18 July 2019; doi:10.1038/s41433-019-0537-5Quantification of anterior chamber reaction after intravitreal injections of conbercept and ranibizumab: a pilot study (Source: Eye)
Source: Eye - July 18, 2019 Category: Opthalmology Authors: Xulong Liao Chuang Jin Weiqi Chen Guihua Zhang Ling-Ping Cen Danny Siu-Chun Ng Haoyu Chen Source Type: research

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
Eye, Published online: 18 July 2019; doi:10.1038/s41433-019-0522-zRelationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data (Source: Eye)
Source: Eye - July 18, 2019 Category: Opthalmology Authors: Srinivas R. Sadda Joanna Campbell Pravin U. Dugel Nancy M. Holekamp Szil árd Kiss Anat Loewenstein Albert J. Augustin Vanessa Shih Xiaoshu Xu Charles C. Wykoff Scott M. Whitcup Source Type: research

Innovative therapies for neovascular age-related macular degeneration.
Authors: Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU Abstract Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies. Areas covered: The authors provide a comprehensive review of investigational therapies for nAMD, focusing on therapies currently in clinical trial. Expert opinion: Long-acting anti-VEGF agents have demonstrated promising results in phase 3 studies, and include Brolucizumab, ...
Source: Expert Opinion on Pharmacotherapy - July 13, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Soluble Tei2 fusion protein inhibits retinopathy of prematurity occurrence via regulation of the Ang/Tie2 pathway.
In conclusion, the combined regulation of the Ang/Tie2 and the vascular endothelial growth factor (VEGF)/VEGF receptor pathways markedly increased the efficacy of treatment with retinal neovascularization (RNV). Regulation of these pathways has a potential for treating RNV, in particular ROP. PMID: 31258697 [PubMed] (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - July 3, 2019 Category: General Medicine Tags: Exp Ther Med Source Type: research

Intravitreal Ranibizumab With Panretinal Photocoagulation Followed by Trabeculectomy Versus Visco-Trabeculotomy in Management of Neovascular Glaucoma
Conclusions: Both VT and Trab-MMC groups are effective in reducing the IOP in cases of NVG after control of neovascularization with anti-vascular endothelial growth factor and pan retinal photocoagulation. (Source: Asia-Pacific Journal of Ophthalmology)
Source: Asia-Pacific Journal of Ophthalmology - July 1, 2019 Category: Opthalmology Tags: Original Clinical Study Source Type: research

Managed care opportunities and approaches to supporting appropriate selection of treatment for sight preservation.
Abstract When evaluating the impact of vision-destroying diseases, pharmacologic therapies represent a significant cost to patients, insurance providers, and society. Currently, up to 11 million people in the United States have some form of age-related macular degeneration (AMD), which is one of the leading causes of vision loss in older Americans. Ophthalmologists have administered more than 6 million intravitreal injections of aflibercept, bevacizumab, pegaptanib, and ranibizumab last year. Comprehensive assessment requires managed care administrators and clinicians to understand the direct and indirect costs of...
Source: The American Journal of Managed Care - July 1, 2019 Category: Health Management Authors: Cannon E Tags: Am J Manag Care Source Type: research

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity.
Authors: Chen X, Zhou L, Zhang Q, Xu Y, Zhao P, Xia H Abstract Background: Retinopathy of prematurity (ROP) is one of the common complications of prematurity. Intravitreal injection of ranibizumab (IVR), an antivascular endothelial growth factor (VEGF) drug, showed significant benefit for ROP. However, there are concerns about systemic complications of anti-VEGF therapy in preterm infants. Objectives: To evaluate serum VEGF level in the systemic circulation after IVR and the complications associated with IVR for the premature infants with ROP. Methods: This prospective investigation assessed the serum conce...
Source: Journal of Ophthalmology - June 28, 2019 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Transscleral sustained ranibizumab delivery using an episcleral implantable device: Suppression of laser-induced choroidal neovascularization in rats
In conclusion, the PEGDM/COL sheet device suppressed CNV via a transscleral administration route for 18 weeks, indicating that prolonged sustained ranibizumab release could reduce the burden of repeated intravitreal injections.Graphical abstract (Source: International Journal of Pharmaceutics)
Source: International Journal of Pharmaceutics - June 25, 2019 Category: Drugs & Pharmacology Source Type: research

ACCURACY AND PRECISION OF INTRAVITREAL INJECTIONS OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN REAL LIFE: What Is Actually in the Syringe?
Purpose: To evaluate the accuracy and precision of anti–vascular endothelial growth factor volume delivery by intravitreal injections in the clinical setup. Methods: Volume output was measured in 669 intravitreal injections administered to patients, calculated from the difference in syringe weight before and after expelling the drug. Three groups were included: prefilled bevacizumab 1.0 mL syringe (Group 1, n = 432), pre-filled ranibizumab in a small-volume syringe with low dead-space plunger design (Group 2, n = 125), and aflibercept drawn and injected using a 1.0-mL syringe (Group 3, n = 112). Accuracy was ana...
Source: RETINA - June 25, 2019 Category: Opthalmology Tags: Original Study Source Type: research

INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial
Purpose: To prospectively investigate the injection frequency of aflibercept and ranibizumab in the treatment of macular edema in central retinal vein occlusion. Methods: Patients with treatment-naive central retinal vein occlusion and macular edema were randomized to receive intravitreal injections with aflibercept (n = 22) or ranibizumab (n = 23) in a treat-and-extend regimen with a follow-up time of 18 months. After 3 loading doses, the treatment intervals were extended by 2 weeks to a maximum of 12 weeks. Intervals were shortened by 2 weeks if macular edema recurred. Results: The number of injections was signif...
Source: RETINA - June 25, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result
Conclusion: The combination therapy of IVR and SMLP can treat branch retinal vein occlusion cystoid macular edema effectively, by decreasing the frequency of IVR injections while maintaining good visual acuity. (Source: RETINA)
Source: RETINA - June 25, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia
Conclusion: Intravitreal ranibizumab provide a 5-year visual benefit in eyes with myopic CNV compared with the natural course. A lack of enlargement of the CNV-related macular atrophy, a better baseline BCVA, and a minimum number of IVR injections were associated with better visual outcomes. (Source: RETINA)
Source: RETINA - June 25, 2019 Category: Opthalmology Tags: Original Study Source Type: research

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
Conclusion: UWFFA-guided TRP reduced the number of injections of Ranibizumab in patients having BRVO with macular edema, while maintaining similar benefits in the improvement of BCVA, central subfoveal thickness without deleterious effect on the visual field, and contrast sensitivity. (Source: Indian Journal of Ophthalmology)
Source: Indian Journal of Ophthalmology - June 25, 2019 Category: Opthalmology Authors: Siddhi Goel Atul Kumar Raghav D Ravani Parijat Chandra Mahesh Chandra Vinod Kumar Source Type: research

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO
To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - June 21, 2019 Category: Opthalmology Authors: Fen Tang, Fan Xu, Haibin Zhong, Xin Zhao, Mingliang Lv, Ke Yang, Chaolan Shen, Hui Huang, Jian Lv, Siming Zeng, Min Li and Qi Chen Tags: Research article Source Type: research

Cancers, Vol. 11, Pages 868: Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
nti Ranjbar Despite the implication of vascular endothelial growth factor-A (VEGF-A) in the pathophysiology of uveal melanoma (UM), the anti-VEGF-A antibody bevacizumab yielded conflicting results on UM growth. Here, we evaluated whether bevacizumab and ranibizumab, a humanized Fab-fragment against VEGF-A, can enter UM cells and induce a sustained physiological response. The primary and metastatic UM cell lines Mel-270 and OMM-2.5 were exposed to bevacizumab or ranibizumab for one day and were maintained further in untreated medium for a total of three days. Both antibodies significantly reduced the levels of extrac...
Source: Cancers - June 21, 2019 Category: Cancer & Oncology Authors: Tura Pawlik Rudolf Ernesti Stutzer Grisanti Ranjbar Tags: Article Source Type: research

Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity
Conclusion: One injection of 0.3 mg intravitreal ranibizumab is effective in treating ROP stage III mainly in zones I and II.Med Princ Pract (Source: Medical Principles and Practice)
Source: Medical Principles and Practice - June 19, 2019 Category: Internal Medicine Source Type: research